TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03622970

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VGBT with Nintendo® Wii and LMC games
Description: Nintendo Wii and LMC games will be used for upper limb rehabilitation in Cerebral Palsy. The games are tennis and boxing for Nintendo Wii, Leapball and CatchApet for LMC.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: NDT-based upper limb rehabilitation
Description: NDT-based upper limb rehabilitation includes using real materials (clothes, spoons, pencils, buttons, rope, etc.) such as getting dressed and eating etc. Also, It will practised with the materials such as velcro cylinders, skill cubes, exercise bands, screw sets, therapeutic putty, and tripled coordination tools.
Study: NCT04225481

Intervention type: OTHER
Intervention: isolation of waste material and culturing with different supplement culture media
Description: isolation of waste material and culturing with different supplement culture media

Intervention type: OTHER
Intervention: isolation of waste material and culturing with different supplement culture media
Description: isolation of waste material and culturing with different supplement culture media
Study: NCT04441944

Intervention type: OTHER
Intervention: Telemedicine
Description: Use of provider-to-provider telemedicine
Study: NCT02111174

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Therapy
Study: NCT02909218

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early Access to ART for All
Description: All HIV-positive individuals will be initiated on Swaziland's recommended first-line ART regimen, unless contraindicated when recommended alternate regimens will be used per national guidelines.
Study: NCT01621776

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Apidra
Description: Subjects on this treatment arm will receive Apidra insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Humalog
Description: Subjects on this treatment arm will receive Humalog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Novolog
Description: Subjects on this treatment arm will receive Novolog insulin for their bolus doses, with doses optimized individually to achieve glycemic targets at daily medical rounds with their cabin physicians. (NOTE: This arm was only for one year of the study which was the 2012 camp session.)
Study: NCT01696955

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tivantinib
Description: Given PO
Study: NCT02259023

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid: Sugar sweetened beverage consumption
Description: Sugar sweetened beverage consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Liquid: Sugar sweetened beverage consumption
Description: Sugar sweetened beverage consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid: Grain based desserts and candy consumption
Description: Grain based desserts and candy consumption

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Solid: Grain based desserts and candy consumption
Description: Grain based desserts and candy consumption
Study: NCT01593605

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Resveratrol
Description: A blend of low dose resveratrol and either leucine or HMB will be useful nutraceutical strategies for the control of elevated blood glucose in non-diabetic individuals with elevated fasting glucose. The proposed project is designed to evaluate this hypothesis by comparing the effects of resveratrol (50 mg)/leucine (1.11 g) administered twice daily (bid).

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: resveratrol /HMB
Description: resveratrol (50 mg)/HMB (500 mg) twice daily (bid) with placebo on fasting blood glucose, glucose tolerance, insulin, C-peptide, glucagon, fructosamine and F2-isoprostanes in non-diabetic subjects with elevated fasting blood glucose.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo treatment
Description: Placebo - one tablet taken twice a day by mouth
Study: NCT04815980

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Home-based mat-based Pilates intervention 3 times a week for 12 weeks prepared by a certified Pilates instructor.
Study: NCT02691390

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active dTMS
Description: dTMS to ACC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham dTMS
Description: SHAM - no stimulation
Study: NCT02264808

Intervention type: OTHER
Intervention: Developmental Outcomes
Description: A Bayley-III developmental assessment will be performed study subjects at age 18-20 months
Study: NCT04990115

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: root canal shaping
Description: root canal treatment

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: root canal shaping
Description: root canal treatment
Study: NCT03923881

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MSOT Acuity Echo
Description: Optoacoustic imaging with the MSOT Acuity Echo
Study: NCT03930095

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance-based Behavior Therapy
Description: The protocol is widely based on Roemer and Orsillo (2007) acceptance model of GAD, using functional assessment, psychoeducation, mindfulness, commitment to valued behavior, and exposure techniques used in a willingness improvement verbal context.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-directive Supportive Therapy
Description: NDST consists in a form of therapeutic intervention from which all intervention principles pertaining to specific psychotherapeutic protocols are removed while maintaining the so-called common factors from different psychotherapy approaches. In other words, it is an unstructured therapy without specific psychological techniques other than those belonging to the basic interpersonal skills of the therapist, such as reflection, empathic listening, encouragement, and helping people to explore and express their experiences and emotions.
Study: NCT00625456

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Vaccinia GM-CSF; RAC VAC GM-CSF (JX-594)
Description: Intravenous Dosage from 1 x 10\^5 pfu/kg to 3 x 10\^7 pfu/kg Intravenous infusion is administered once over a 60 minute period
Study: NCT01693913

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: cognitive behavioral exercise and nutrition over

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: nutrition and exercise education
Study: NCT04038112

Intervention type: OTHER
Group type: OTHER
Intervention: psychological therapy Method of Levels (MOL)
Description: Transdiagnostic, cognitive psychological therapy Method of Levels (MOL)
Study: NCT00121719

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenvatinib
Description: Lenvatinib tablets taken orally, once daily.
Study: NCT03588897

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Nutridrink Multi Fibre
Description: Dietary supplementation of 300 kcal for 14 days
Study: NCT01145664

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herbal concentrate-granules plus western therapy
Description: Intervention time: 7-10 days; Follow-up time: 5 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduning Injection plus western therapy
Description: Intervention time: 7-10 days; Follow-up time: 5 days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Western therapy
Description: Intervention time: 7-10 days; Follow-up time: 5 days.
Study: NCT00484770

Intervention type: DEVICE
Group type: OTHER
Intervention: Brain Natriuretic Peptide Levels -- Diagnostic testing

Intervention type: OTHER
Group type: OTHER
Intervention: clinical assessment

Intervention type: OTHER
Group type: OTHER
Intervention: clinical assessment
Study: NCT01348724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [14C] NKTR-118
Description: Single 25 mg oral dose administered on Day 1
Study: NCT02492893

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hatha yoga
Study: NCT02855489

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Attitudes Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Norms Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Perceived Behavioral Control Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intentions Only

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Three Constructs

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Four Constructs
Study: NCT04809441

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet change
Description: A specific very low-calorie diet (\<800kcal/day), and 2 daily sessions of 15 minutes of anaerobic physical exercise depending on the capacity of the participants, were designed
Study: NCT01404429

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Different doses for both arms followed by similar escalation (2.5 mg every 15 d) till max of 25 mg per week or 3 months completed
Study: NCT04662229

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eco-guided Percutaneous Electrical Stimulation
Description: Pointer 10 hz. A symetric, biphasic current of 10 hz and 240 microsecond. The stimulation intensity will be reaching the excitomotor threshold, producing visible but comfortable contractions.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Application of the needles only on the median and ulnar nerve of the arm, for 1 minute on each nerve without current intensity and applying a son.
Study: NCT02830477

Intervention type: BIOLOGICAL
Intervention: Kovaltry (Antihemophilic Factor [Recombinant], BAY81-8973
Description: unmodified, full length recombinant FVIII
Study: NCT04058275

Intervention type: OTHER
Intervention: Draw blood (phlebotomy, 83 ml)
Description: Draw 83 ml of blood

Intervention type: OTHER
Intervention: Draw blood (phlebotomy, 83 ml)
Description: Draw 83 ml of blood
Study: NCT03752970

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Spesolimab
Description: Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spesolimab
Description: Spesolimab 1200 milligram intravenously every 4 weeks (week 0, 4, 8, 12, 16 and 20). At week 12 Placebo patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo intravenously every 4 weeks (week 0, 4, 8). At week 12 achievement of combined perianal fistula remission was determined, patients without combined perianal fistula remission were switched to spesolimab and were treated with spesolimab 1200 milligram intravenously every 4 weeks (week 12, 16 and 20). Patients with combined perianal fistula remission remained on Placebo and were treated with placebo intravenously every 4 weeks (week 12, 16 and 20).
Study: NCT02583529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Back Tibial Nerve Electrostimulation
Description: The BTNE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Electrostimulation
Description: The BTNPE will be made with electrodes Silver Spike Point (SSP) set in an ankle with the negative pole positioned on the inner malleolus and the positive approximately 05 cm below the previous, and connected to a portable stimulator powered by rechargeable battery developed by the Biomedical Engineering Department of the HCPA.
Study: NCT01013038

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration followed by stent implantation
Description: Export aspiration catheter 6F (Medtronics)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: conventional PCI
Description: balloon angioplasty and/or stent implantation
Study: NCT03556800

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel
Description: Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel
Description: Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Estrogel
Description: Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Estrogel
Description: Each subject will receive the following IMPs in accordance with the randomisation code:~* Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream~* Reference IMP: a single-dose of 1.25g EstroGel
Study: NCT02200653

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High dose of MICARDIS®, once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low dose of MICARDIS®, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Low dose of COZAAR® / LORZAAR®, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High dose of COZAAR® / LORZAAR®, once daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00368927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sulindac
Description: Given orally

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT04654572

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric measurement
Description: Myotonometric assessment can predict the muscle stiffness, tone and elasticity

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Myotonometric measurement
Description: Myotonometric assessment can predict the muscle stiffness, tone and elasticity
Study: NCT00878826

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin
Description: Drug: Enoxaparin 40 mg every morning until 36 weeks gestation. Drug: Enoxaparin 1 mg per kg every morning until 36 weeks gestation. Dose will increase at wt. increases.~Drug: Enoxaparin dose taken by patient when enrolled until 36 weeks gestation.
Study: NCT02985840

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron
Description: Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Patients receive intravenous ondansetron (4mg) followed by two 5ml normal saline flushes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Patients receive intravenous ondansetron(4mg) followed by intravenous dexamethasone (4mg), followed by a single 5ml normal saline flush
Study: NCT00144495

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: 3600IU(s.c.)/week for 7 weeks and 54000IU(s.c.)/week for 5 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant human erythropoietin
Description: 36000IU(s.c.)/week for 12 weeks
Study: NCT02595775

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Individualized A/F report
Description: Individualized A/F report containing 9 colonoscopy quality measures.

Intervention type: OTHER
Group type: OTHER
Intervention: Individualized A/F report
Description: Individualized A/F report containing 9 colonoscopy quality measures.

Intervention type: OTHER
Group type: OTHER
Intervention: A/F report plus a high intensity intervention
Description: E.g. Master class in colonoscopy

Intervention type: OTHER
Group type: OTHER
Intervention: A/F report plus a low intensity intervention
Description: E.g. Access to a video/presentation on good colonoscopy technique followed by a post presentation assessment.

Intervention type: OTHER
Group type: OTHER
Intervention: A/F report alone
Study: NCT02294526

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sardine diet
Description: Diet rich in sardine: 100g/day of sardine 5 times a week
Study: NCT03235752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ301 300mg
Description: TJ301 300mg IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TJ301 600mg
Description: TJ301 600mg IV infusion

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo IV infusion
Study: NCT04068233

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacemaker stimulation mode
Description: Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pacemaker stimulation mode
Description: Echocardiographic indices are measured during AV asynchronous and AV synchronous pacemaker stimulation.
Study: NCT02878707

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexmedetomidine
Description: Intraoperative dexmedetomidine infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Intraoperative dexmedetomidine infusion
Study: NCT00624247

Intervention type: OTHER
Group type: OTHER
Intervention: routine HIV testing
Description: Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.

Intervention type: OTHER
Group type: OTHER
Intervention: routine HIV testing
Description: Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.

Intervention type: OTHER
Group type: OTHER
Intervention: routine HIV testing
Description: Potential subjects are offered swabbing as part of HIV testing by jail medical staff or study staff. All potential subjects are told HIV results can now be made available within a short period of time using an oral swab. Anyone not wanting HIV test results is allowed to refuse at the time of offering the HIV test and not be swabbed. If the inmate agrees to be swabbed and tested, he or she then meets with a member of the research study staff who discusses two separate informed consents - one for study participation and one for HIV testing.
Study: NCT02912637

Intervention type: OTHER
Intervention: Hyperpolarized Xenon MRI
Description: MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent

Intervention type: OTHER
Intervention: Hyperpolarized Xenon MRI
Description: MRI \& MRS of lung using inhaled hyperpolarized Xenon as a contrast agent
Study: NCT02574169

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alveolar recruitment maneuvers group 1
Description: Patients are randomized to receive in cross-over 2 ARM: CPAP at first and then eSigh.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: alveolar recruitment maneuvers group 2
Description: Patients are randomized to receive in cross-over 2 ARM: eSigh at first and then CPAP.~The eSigh or extended sigh with increase of PEEP for 10 minutes to maintain plateau pressure at 40 cmH2O. During ARM, the peak pressure is limited to 50 cmH2O with decrease of tidal volume (Vt) if necessary.~The continuous positive airway pressure, or CPAP with application of a positive pressure of 40 cmH2O for 40 seconds without tidal volume.~The following data: PtiO2, respiratory parameters, systemic and intracerebral hemodynamic parameters are collected before, after 1 minute, 10 minutes and 60 minutes for each ARM.